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Background: Polycystic ovary syndrome (PCOS) is associated with an increased cardiovascular disease (CVD) risk
and early atherosclerosis. Epicardial adipose tissue thickness (EATT) is clinically related to subclinical atherosclerosis.
In the present study, considering the major role of neutrophil gelatinase-associated lipocalin (NGAL) which is an
acute phase protein rapidly releasing upon inflammation and tissue injury, we aimed to evaluate NGAL levels and
EATT in PCOS patients and assess their relationship with cardiometabolic factors.
Methods: 64 patients with PCOS and 50 age- and body mass index-matched healthy controls were included in the
study. We evaluated anthropometric, hormonal and metabolic parameters. EATT was measured by echocardiography
above the free wall of the right ventricle. Serum NGAL and high-sensitive C- reactive protein (hsCRP) levels were
measured by ELISA.
Results: Mean EATT was 0,38 +/-0,16 mm in the PCOS group and 0,34 +/-0,36 mm in the control group (p = 0,144). In
the obese PCOS group (n = 44) EAT was thicker compared to the obese control group (n = 41) (p = 0.026). Mean NGAL
levels of the patients with PCOS were 101,98 +/-21,53 pg/ml, while mean NGAL levels were 107,40 +/-26,44 pg/ml in
the control group (p = 0,228). We found a significant positive correlation between EATT and age, BMI, waist
circumference, fasting insulin, HOMA-IR, triglyceride and hsCRP levels in PCOS group.
Conclusions: Thickness of the epicardial adipose tissue can be used to follow the risk of CVD development in obese
PCOS cases. However serum NGAL levels do not differ in patients with PCOS and control group.
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Polycystic ovary syndrome (PCOS) is a common endo-
crine disorder that affects about 5-10% of women of re-
productive age and characterized by hyperandrogenism,
menstrual disturbance, chronic anovulation and infertility
[1]. PCOS is frequently associated with multiple risk fac-
tors for coronary heart disease (CHD), including insulin
resistance (IR), dyslipidemia, visceral obesity and hyper-
tension [2,3]. It is reported to be associated with elevation
of various markers of endothelial inflammation and abnor-
mal endothelial function which plays a critical role in* Correspondence: serapbaydur@gmail.com
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unless otherwise stated.cardiovascular disease and in particular in the develop-
ment and progression of atherosclerosis [4].
Neutrophil gelatinase-associated lipocalin (NGAL),
also known as lipocalin-2 is an acute phase protein, that
is rapidly released from neutrophils upon inflammation
and tissue injury [5]. Additionally, it has been found to
be expressed in several types of cells, including kidney
tubular cells, adipocytes, macrophages, brain endothe-
lial cells and hepatocytes [6,7]. NGAL has been impli-
cated in some pathophysiological processes, including
apoptosis, iron transport, inflammation, cell survival,
tumorigenesis, and atherosclerosis [6,7]. Evidence sug-
gests that NGAL plays an important role in systemic in-
sulin sensitivity and glucose homeostasis [8,9]. In a recent
study, NGAL was determined to reflect the degree of in-
flammatory process in coronary artery disease [10].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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around the heart, between the myocardium and visceral
epicard [11]. It mediates atherosclerosis via expression of
several bioactive molecules [12] and has been reported
to reflect the intraabdominal visceral fat [13]. Epicardial
adipose tissue thickness (EATT) has been demonstrated to
correlate with the severity of coronary artery disease (CAD)
and the extent of coronary artery atherosclerosis [14-16].
In this study, our aim was to measure NGAL levels
and EATT in women with PCOS and compare them
with those of age and body mass index (BMI)-matched




This study included 66 patients with PCOS and age- body
mass index (BMI) matched 50 healthy controls. Women
were all of the same ethnicity. All the patients gave a writ-
ten consent. This study was approved by the Institutional
Ethical Committee of the institution in which this study
was conducted. All the patients were nonsmokers.
The diagnosis of PCOS was made according to the
Rotterdam European Society for Human reproduction
and Embryology/American Society for Reproductive
Medicine– sponsored PCOS Consensus Workshop Group
[17]. The revised diagnostic criteria of PCOS is as follows,
with at least two of the following being required: i) Oligo
and/or anovulation that is menstrual disturbance, ii) Clin-
ical and/or biochemical signs of hyperandrogenism, iii)
Polycystic ovarian appearance on ultrasound examination.
Clinical hirsutism was defined by a modified Ferriman-
Gallwey score of more than eight.
Patients and healthy subjects who had smoking his-
tory, diabetes mellitus, thyroid disorders, hyperprolactine-
mia, non-classical congenital adrenal hyperplasia (NCAH),
androgen-secreting tumours, Cushing syndrome (1 mg
dexamethasone suppression test), infection diseases, hyper-
tension, hepatic or renal dysfunction were excluded from
the study. The other exclusion criteria were; drug use
within 3 months such as oral contraceptive agents, antilipi-
demic and hypertensive drugs, and insulin-sensitizing
drugs. For the exclusion of NCAH, we measured 17OH-
progesterone levels in the all patients. The patients who
had basal 17OH-progesterone levels >4 ng/ml were diag-
nosed as NCAH. We performed ACTH stimulation test in
patients who had >2 ng/ml 17-OHP levels. The diagnosis
of NCAH was considered in patients with the poststimula-
tion 17-OHP level exceed 10 ng/ml. These patients were
not included in the study. We selected healthy volunteers
from the subjects working at our hospital and students in
our medical school and nursing school. Control group
(n = 50) consisted of healthy patients who had hirsutism
score <8, regular menses, every 21–35 days and normalandrogen levels None of the women in the control group
had polycystic ovary in ultrasound.
Clinical, biochemical and hormonal measurements
Weight, height, waist circumference and systolic and
diastolic blood pressure (BP) were measured. The BMI
was calculated by dividing the body weight in kilograms
by the square of the height in meters (kg/m2). Waist cir-
cumference was measured at the narrowest level be-
tween the costal margin and iliac crest. The BMI, waist
circumference and hirsutism scores were assessed by a
single investigator for all of the subjects.
Venous blood samples were obtained from all sub-
jects following an 8–12 h overnight fast in the follicu-
lar phase of a spontaneous or progesterone induced
menstrual cycle. The levels of fasting glucose, insulin, total
cholesterol, triglyceride (TG), high-density lipoprotein chol-
esterol (HDL-cholesterol), low-density lipoprotein chol-
esterol (LDL-cholesterol) and high-sensitive C-reactive
protein (hs-CRP) were measured. All the patients under-
went a 75 gr oral glucose tolerance test (OGTT). An insulin
resistance score Homeostasis Model Assessment-Insulin re-
sistance (HOMA-IR) was computed by the following for-
mula [18]: HOMA-IR = fasting plasma glucose (mmol/L) ×
fasting serum insulin (mU/mL)/22.5. The cut off value was
taken 2.7 for HOMA-IR [19].
The hexokinase method was used to measure glucose
levels, and photometric method (Abbott Architect c16000
otoanalyzer) was used to measure the total cholesterol,
triglyceride (TG), high-density lipoprotein cholesterol
(HDL-cholesterol), and low-density lipoprotein cholesterol
(LDL-cholesterol) levels. Insulin was measured using CMIA
(Chemiluminescent microparticle immunoassay) (Abbott,
Architect system, USA). The concentration of high-sensitive
C- reactive protein (hsCRP) was measured using immuno-
tubidimetric method with Abbott Architect C16000 otoana-
lyzer (Abbott Diagnostic, USA). The cut off for hsCRP was
taken <0.5 mg/dl.
Serum levels of insulin, follicle-stimulating hormone
(FSH), luteinizing hormone (LH), prolactin, dehydroepian-
drosterone sulfate (DHEAS), total testosterone, insulin and
thyroid stimulating hormone (TSH) were measured using
chemiluminescent microparticle enzyme immunoassay
(CMIA) method with Abbott Architect i2000 (Abbott Diag-
nostic, USA). Serum 17 hydroxyprogesterone and free tes-
tosterone were measured by radioimmunoassay.
Measurement of NGAL
The serum levels of NGAL were measured using enzyme-
linked immunosorbent assay (ELISA) method. We used
commercially available human NGAL ELISA kit (MyBio-
source, USA). The procedure for the ELISA method was
according to the instructions provided by the manufacturer.
Absorbance was measured at a wavelength of 450 ηm using
Table 1 The clinical, biochemical and hormonal results in
women with polycystic ovary syndrome (PCOS) patients
and healthy controls
Parameter PCOS group Control group p
(n = 66) (n = 50)
Age (years) 23.29 ±5.05 22.02 ±5.05 0.183
BMI (kg/m2) 32.09 ±9.80 29.80 ±5.5 0.148
Waist circumference (cm) 8.67 ±19.37 92.28 ±13.30 0.048
Systolic blood pressure (mmHg) 126.77 ±14.15 113.22 ±9.99 0.0001
Diastolic blood pressure (mmHg) 76.18 ±11.37 68.20 ±6.74 0.0001
Fasting insulin (μIU/ml) 11.16 ±6.58 9.47 ±6.06 0.160
Fasting glucose (mg/dl) 97.30 ±13.97 89.10 ±10.56 0.001
HOMA-IR 2.71 ±1.7 2.16 ± 1.5 0.072
Total cholesterol (mg/dl) 194.81 ±39.55 173.28 ±29.99 0,002
Triglyceride (mg/dl) 115.91 ±58.18 93.30 ±39.30 0.020
HDL-C (mg/dl) 49.61 ±11.09 47.08 ±10.30 0.213
LDL-C (mg/dl) 122.83 ±34.43 107.0 ±24.64 0.007
hsCRP (mg/dl) 0.54 ±0.95 0.19 ±0.31 0.015
TSH (μIU/ml) 2.11 ±1.47 2.58 ±3.24 0.295
Prolactin (ng/ml) 18.3 ± 15.4 17.4 ± 6.9 0.590
Total testosterone (ng/ml) 0.85 ± 0.3 0.56 ± 0.1 0.0001
FSH (mIU/ml) 4.5 ± 1.2 4.5 ± 0.7 0.950
LH (mIU/ml) 5.7 ± 2.7 3.5 ± 0.5 0.0001
Estradiol (pg/ml) 43.9 ± 33.3 41.02 ± 3.1 0.536
DHEAS (μg/dl) 266.3 ± 123 203.85 ± 40.3 0.0001
Free testosterone (pg/ml) 3,3 ± 2.3 2.3 ± 0.4 0.008
EATT (mm) 0.38 ±0.16 0.34 ±0.36 0.144
NGAL (pg/ml) 101.98 ±21.53 107.40 ±26.44 0.228
Values are expressed as means ± SD. BMI body mass index, HOMA-IR homeostasis
model assessment insulin resistance index, HDL-C high density lipoprotein
cholesterol, LDL-C low density lipoprotein cholesterol, hs-CRP high-sensitive
C- reactive protein, TSH thyroid stimulating hormone, FSH follicle-stimulating
hormone, LH luteinizing hormone, DHEAS dehydroepiandrosterone sulfat,
EATT epicardial adipose tissue thickness, NGAL neutrophil
gelatinase-associated lipocalin.
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The intra-assay and inter-assay coefficient of variation were
4.1% and 3.9%, respectively. The limit of detection (LOD)
for the NGAL assay was <10 pg/ml.
Measurement of epicardial adipose tissue thickness
All patients underwent 2D Doppler echocardiography
with a Philips IE-33 system and S5-1 transducer (1e5 mHz,
Philips, Bothell, WA, USA). The epicardial fat thickness
(EFT) was identified as the echo-free space between the
outer wall of the myocardium and the visceral layer of the
pericardium, and its thickness was measured perpendicu-
larly on the free wall of the right ventricle at end-systole in
three cardiac cycles. Parasternal long- and short-axis views
were used. The average value of three cardiac cycles from
each echocardiographic view was considered [20,21]. All
the measurements were done by the same cardiologist.
Statistical analysis
Data were analyzed using SPSS Software (Version 17,
SPSS, Inc., Chicago, IL, USA). Results were expressed as
mean ± standard deviation. The Mann–Whitney U test
was used to compare the continuous variables and the
Chi-square test was used to compare categorical variables.
Spearman’s rank correlation test was used for calculation
of associations between variables. A p value of less than
0.05 was considered to be statistically significant.
Results
We enrolled 66 patients with PCOS (mean age;
23,29 ±5,05 years, BMI; 32,09 ±9,80 kg/m2) and 50
age and BMI matched healthy control group (mean age;
22,02 ±5,05 years, BMI; 29,80 ±5,5 kg/m2) in the current
study. The clinical and biochemical results of the study
population are shown in Table 1.
Fasting plasma glucose, hsCRP, triglyceride, total and
LDL cholesterol levels were significantly higher in
women with PCOS (Table 1).
Mean EATT was 0,38 ±0,16 mm in the PCOS group
and 0,34 ±0,36 mm in the control group (p = 0,144). Al-
though EATT was higher in PCOS patients, the difference
did not reach statistical significance. We found a signifi-
cant correlation between EATT and age, BMI, waist cir-
cumference, fasting insulin, HOMA-IR, triglyceride and
hsCRP in the patients with PCOS (Table 2). In the control
group, EATT was also associated with.
Mean NGAL levels of the patients with PCOS were
101,98 ±21,53 pg/ml, while mean NGAL levels were
107,40 ±26,44 pg/ml in the control group (p = 0,228).
Serum NGAL levels were not correlated with the meta-
bolic parameters in both of the groups (Table 3).
The patients with PCOS were divided into 2 groups
according to the HOMA-IR levels. The cut-off point was
2.7 [22]. 28 PCOS patients had an HOMA-IR greaterthan 2.7, while 38 patients had an HOMA-IR lower than
2.7. EATT and hsCRP levels were higher in the insulin
resistant group, however NGAL levels were similar in
both of the groups (Table 4). The insulin resistant con-
trol group (n = 14) had also higher hsCRP levels, but
EATT was similar.
When we evaluate the PCOS patients according to the
hsCRP values, 16 patients had hsCRP values higher than
0.5 mg/L and EATT was found to be higher in this sub-
group (p = 0.007). In the control group, 4 patients had
hsCRP levels ≥ 0.5 mg/L and EATT was similar in the
PCOS and control group. NGAL levels did not differ in
both of the groups according to hsCRP levels.
When we divide the PCOS patients according to BMI,
21 patients had BMI < 25 kg/m2. We compared the lean
and obese patients with PCOS and found that NGAL and
Table 2 The correlation between epicardial adipose tissue
thickness and metabolic parameters in patients with
PCOS and control group
Parameter PCOS group (n = 66) Control group (n = 50)
r p value r p value
Age 0,248 0,045* 0,231 0,106
BMI 0,641 0,0001** 0,314 0,027*
WC 0,563 0,0001** 0,258 0,070
FG score 0,061 0,626
Fasting glucose 0,072 0,565 0,137 0,342
Fasting insulin 0,472 0,0001** 0,088 0,545
HOMA-IR 0,641 0,0001** 0,300 0,034*
Total cholesterol 0,216 0,081 0,299 0,035*
Triglyceride 0,363 0,003** 0,382 0,006**
LDL cholesterol 0,213 0,085 0,274 0,054
HDL cholesterol −0,200 0,108 −0,243 0,093
hsCRP 0,324 0,008** 0,096 0,507
NGAL 0,086 0,494 −0,051 0,727
TSH −0,110 0,377 0,010 0,946
Estradiol 0,026 0,834 0,029 0,846
LH/FSH −0,367 0,068
DHEAS −0,133 0,286 −0,011 0,939
Total testosterone 0,185 0,137 0,078 0,596
r indicates Spearman’s rho correlation coefficient; *Correlation is significant at
the 0.05 level. **Correlation is significant at the 0.01 level. a log transformed.
BMI body mass index, HOMA-IR homeostasis model assessment insulin
resistance index, HDL-C high density lipoprotein cholesterol, LDL-C low density
lipoprotein cholesterol, hs-CRP high-sensitive C- reactive protein, NGAL
neutrophil gelatinase-associated lipocalin, TSH thyroid stimulating hormone,
FSH follicle-stimulating hormone, LH luteinizing hormone, DHEAS
dehydroepiandrosterone sulfat.
Table 3 The correlation between NGAL levels and
metabolic parameters in patients with PCOS




FG score 0,051 0,684
Fasting glucose 0,088 0,487
Fasting insulin −0,109 0,880
HOMA-IR 0,031 0,808
Total cholesterol 0,013 0,917
Triglyceride 0,037 0,772
LDL cholesterol 0,019 0,882







Total testosteron −0,043 0,733
r indicates Spearman’s rho correlation coefficient. BMI body mass index,
HOMA-IR homeostasis model assessment insulin resistance index, HDL-C high
density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol,
hs-CRP high-sensitive C- reactive protein, EATT epicardial adipose tissue
thickness, TSH thyroid stimulating hormone, FSH follicle-stimulating hormone,
LH luteinizing hormone, DHEAS dehydroepiandrosterone sulfat.
Sahin et al. Journal of Ovarian Research 2014, 7:24 Page 4 of 6
http://www.ovarianresearch.com/content/7/1/24hsCRP levels were similar in both of the groups. How-
ever HOMA-IR and EATT was higher in the obese pa-
tients (p = 0.001, p = 0.007). In the control group, 41
patients had BMI > 25 kg/m2 and EATT, serum NGAL
and hsCRP levels did not differ in the obese and healthy
subjects (p = 0.902, p = 0.057, p = 0.342). When we com-
pared the obese PCOS (n = 44) and obese control group
(n = 41), EAT was thicker in the PCOS group (p =
0.026), however NGAL levels did not differ (Table 5).
Discussion
Our study shows that epicardial adipose tissue thickness is
higher in obese PCOS patients compared with obese con-
trol subjects, however NGAL levels are similar in both of
the groups. We demonstrated that EATT was positively
correlated with age, BMI, waist circumference, fasting in-
sulin, HOMA-IR, triglyceride and hsCRP levels. Therefore,
EATT can be used to follow the risk of CVD development
in obese PCOS cases.
Women with PCOS have multiple risk factors for car-
diovascular disease (CVD) and is considered as a majorlong-term health risk. The risk factors for premature ath-
erosclerosis and CVD, such as increased central adiposity,
elevated blood pressure, higher total and LDL cholesterol
levels, higher triglyceride levels, and higher plasma glucose
levels were more prevalent in our PCOS population, com-
pared with matched-for-age and BMI control women, as
have been shown in previous studies [23,24]. These meta-
bolic risk factors may predict the development of athero-
sclerosis in women with PCOS.
Although an increase in mortality due to coronary ar-
tery disease in patients with PCOS was not shown in
the long term follow up [2], there is strong evidence
that women with PCOS are at increased risk of meta-
bolic cardiovascular syndrome [25]. In a study, coronary
artery calcification was evaluated in younger women
with PCOS 30–45 years as a measure of subclinical ath-
erosclerotic disease burden, and it was found to be more
prevalent in PCOS women [3]. In the other study, post-
menopausal women noted 2.5 higher odds of obstructive
coronary artery disease for those with clinical features of
PCOS, even when controlling for metabolic and common
cardiac risk factors [26].
Highly sensitive C-reactive protein (hsCRP) levels are
good predictors of subclinical atherosclerosis and vascular
Table 4 The comparison of PCOS and control group according to HOMA-IR levels
Variable HOMA-IR ≥ 2.7 HOMA-IR < 2.7 p HOMA-IR ≥ 2.7 HOMA-IR < 2.7 p
PCOS group PCOS group Control group Control group
(n = 28) (n = 38) (n = 14) (n = 36)
EATT (mm) 0.44 ± 1.1 0.34 ± 1.4 0.019 0.35 ± 0.16 0.33 ± 0.12 0.592
NGAL (pg/ml) 100.4 ± 23.2 103.1 ± 20.3 0.610 113.5 ± 21.4 105 ± 28.1 0.310
hsCRP (mg/dl) 0.89 ± 1.1 0.27 ± 0.6 0.009 0.38 ± 0.5 0.11 ± 0.14 0.004
BMI (kg/m2) 37.5 ± 10.3 28.1 ± 7.3 0.0001 34.06 ± 5.5 28.1 ± 4.6 0.0001
Values are expressed as means ± SD.
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levels in women with PCOS [22,27] in contrast to others
that say it is related only to obesity [28]. In our study,
serum hsCRP levels were significantly higher in women
with PCOS than the controls and it was correlated with
BMI, EATT and decreased insulin sensitivity. Kim et al.
have reported higher hsCRP levels even in lean PCOS
women [22]. In our study, hsCRP levels did not differ in
lean PCOS and lean control subjects.
NGAL is highly expressed in adipocytes, that its ex-
pression is regulated by obesity, and that it induces insu-
lin resistance [8]. Studies investigating the relationship
between NGAL levels and PCOS found confusing re-
sults. Cakal E et al. demonstrated that NGAL levels were
higher in PCOS patients and was related with insulin re-
sistance [29]. However, in the other study, NGAL levels
were found to be lower in PCOS patients [30]. In our
study, NGAL levels were similar in PCOS patients and
healthy subjects. NGAL measurements also did not dif-
fer in groups based on the HOMA-IR and hsCRP levels
and BMI.
In the recent studies it was found that serum levels of
NGAL were significantly elevated in patients with angio-
graphically confirmed CAD compared to those with nor-
mal arteries or controls [10,31,32]. The authors explain
that these diffrences can result because of the expression
of NGAL from vascular cells during atherogenesis. In
our study, NGAL levels did not correlate with the car-
diometabolic risk factors.
Epicardial adipose tissue thickness is clinically related
to abdominal visceral adiposity which has significant
impact on cardiovascular diasease risk [13]. In recentTable 5 The comparison of obese PCOS and control subjects
Obese PCOS group Obese control group p
(n = 44) (n = 41)
EATT (mm) 0.42 ± 0.1 0.34 ± 0.1 0.026
NGAL (pg/ml) 104.2 ± 22.9 110.7 ± 27.1 0.235
HOMA-IR 3.1 ± 1.7 2.4 ± 1.5 0.045
hsCRP (mg/dl) 0.62 ± 0.9 0.21 ± 0.33 0.012
Values are expressed as means ± SD.studies, EATT was found to be associated with coronary
heart diseases [14-16].
There are only few studies evaluating the EATT in
PCOS patients and in both of the studies EAT was thicker
in the PCOS patients [33,34]. In our study, EAT was
thicker in the PCOS group, but the difference was not sig-
nificant. EATT was associated with the cardiometabolic
risk factors, such as HOMA-IR and triglyceride in PCOS
and control group. EATT was also associated with hsCRP
in the PCOS patients, while it was not in the control
group. When we compared the PCOS and control
group according to HOMA-IR, hsCRP levels and BMI,
we showed that EAT was thicker in the PCOS group
who were obese and had higher HOMA-IR and hsCRP
levels. However we did not demonstrate such a rela-
tionship in the control group. Additionally, in obese
PCOS patients EATT was higher compared to obese
healthy subjects. All obese subjects, whether PCOS or
controls had similar EATT compared to the lean sub-
jects. Therefore, we suggest that obesity does not solely
influence EATT.
In conclusion, measurement of epicardial adipose tis-
sue thickness is a non-invasive tool and easy to perform
and appears to be a good method to follow the risk of
cardiovascular disease development in obese and insulin
resistant PCOS patients.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
SBS, MCC and MB conceived the study and participated in its design. YU and
EE performed the ultrasound examinations. SBS, EUG, NA and MB
participated in the analysis and interpretation of data. SBS, NA and EUG
collected the data. SBS, MCC, YU, EE, EUG, NA and MB wrote the paper.
All authors read and approved the final manuscript.
Author details
1Department of Endocrinology and Metabolism Disease, Recep Tayyip
Erdogan University Medical School, Rize, Turkey. 2Department of
Biochemistry, Recep Tayyip Erdogan University Medical School, Rize, Turkey.
3Department of Cardiology, Recep Tayyip Erdogan University Medical School,
Rize, Turkey. 4Department of Internal Medicine, Recep Tayyip Erdogan
University Medical School, Rize, Turkey. 5Department of Endocrinology and
Metabolism Disease, Recep Tayyip Erdogan University Training and Research
Hospital, 53020 Rize, Turkey.
Sahin et al. Journal of Ovarian Research 2014, 7:24 Page 6 of 6
http://www.ovarianresearch.com/content/7/1/24Received: 30 October 2013 Accepted: 11 February 2014
Published: 16 February 2014References
1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO: The
prevalence and features of the polycystic ovary syndrome in an
unselected population. J Clin Endocrinol Metab 2004, 89(6):2745–2749.
2. Wild S, Pierpoint T, McKeigue P, Jacobs H: Cardiovascular disease in
women with polycystic ovary syndrome at long-term follow-up: a
retrospective cohort study. Clin Endocrinol (Oxf ) 2000, 52(5):595–600.
3. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF 2nd,
Fitzpatrick LA: Prevalence and predictors of coronary artery calcification
in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003,
88(6):2562–2568.
4. Ross R: Atherosclerosis–an inflammatory disease. N Engl J Med 1999,
340(2):115–126.
5. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, et al:
Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc
Nephrol 2007, 18(2):407–413.
6. Chen X, Jia X, Qiao J, Guan Y, Kang J: Adipokines in reproductive function:
a link between obesity and polycystic ovary syndrome. Mol Endocrinol
2013, 50(2):R21–R37.
7. Zhang J, Wu Y, Zhang Y, Leroith D, Bernlohr DA, Chen X: The role of
lipocalin 2 in the regulation of inflammation in adipocytes and
macrophages. Mol Endocrinol 2008, 22(6):1416–1426.
8. Yan QW, Yang Q, Mody N, Graham TE, Hsu CH, Xu Z, et al: The adipokine
lipocalin 2 is regulated by obesity and promotes insulin resistance.
Diabetes 2007, 56(10):2533–2540.
9. Wang Y, Lam KS, Kraegen EW, Sweeney G, Zhang J, Tso AW, et al: Lipocalin-2
is an inflammatory marker closely associated with obesity, insulin
resistance, and hyperglycemia in humans. Clin Chem 2007, 53(1):34–41.
10. Kafkas N, Demponeras C, Zoubouloglou F, Spanou L, Babalis D, Makris K:
Serum levels of gelatinase associated lipocalin as indicator of the
inflammatory status in coronary artery disease. Int J Inflam 2012,
2012:189797.
11. Iacobellis G, Corradi D, Sharma AM: Epicardial adipose tissue: anatomic,
biomolecular and clinical relationships with the heart. Nat Clin Pract
Cardiovasc Med 2005, 2(10):536–543.
12. Baker AR, Silva NF, Quinn DW, Harte AL, Pagano D, Bonser RS, et al:
Human epicardial adipose tissue expresses a pathogenic profile of
adipocytokines in patients with cardiovascular disease.
Cardiovasc Diabetol 2006, 5:1.
13. Iacobellis G, Assael F, Ribaudo MC, Zappaterreno A, Alessi G, Di Mario U, et al:
Epicardial fat from echocardiography: a new method for visceral adipose
tissue prediction. Obes Res 2003, 11(2):304–310.
14. Ahn SG, Lim HS, Joe DY, Kang SJ, Choi BJ, Choi SY, et al: Relationship of
epicardial adipose tissue by echocardiography to coronary artery
disease. Heart 2008, 94(3):e7.
15. Eroglu S, Sade LE, Yildirir A, Bal U, Ozbicer S, Ozgul AS, et al: Epicardial
adipose tissue thickness by echocardiography is a marker for the
presence and severity of coronary artery disease. Nutr Metab Cardiovasc
Dis 2009, 19(3):211–217.
16. Djaberi R, Schuijf JD, van Werkhoven JM, Nucifora G, Jukema JW, Bax JJ:
Relation of epicardial adipose tissue to coronary atherosclerosis. Am J
Cardiol 2008, 102(12):1602–1607.
17. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group:
Revised 2003 consensus on diagnostic criteria and long-term health risks
related to polycystic ovary syndrome. Fertil Steril 2004, 81:19–25.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC:
Homeostasis model assessment: insulin resistance and beta-cell function
from fasting plasma glucose and insulin concentrations in man.
Diabetologia 1985, 28:412–419.
19. Gokcel A, Ozsahin AK, Sezgin N, et al: High prevalence of diabetes in
Adana, a southern province of Turkey. Diabetes Care 2003, 26:3031–3034.
20. Iacobellis G, Willens HJ, Barbaro G, Sharma AM: Threshold values of high-risk
echocardiographic epicardial Fat thickness. Obesity (Silver Spring) 2008,
16(4):887–892.
21. Mariani S, Fiore D, Barbaro G, Basciani S, Saponara M, D’Arcangelo E, et al:
Association of epicardial fat thickness with the severity of obstructive
sleep apnea in obese patients. Int J Cardiol 2013, 167(5):2244–2249.22. Kim JW, Han JE, Kim YS, Won HJ, Yoon TK, Lee WS: High sensitivity
C-reactive protein and its relationship with impaired glucose regulation
in lean patients with polycystic ovary syndrome. Gynecol Endocrinol 2012,
28(4):259–263.
23. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, et al: Coronary
heart disease risk factors in women with polycystic ovary syndrome.
Arterioscler Thromb Vasc Biol 1995, 15(7):821–826.
24. Graf M, Richards C, Brown V, Meissner L, Dunaif A: The independent effects
of hyperandrogenaemia, hyperinsulinaemia and obesity on lipid and
lipoprotein profiles in women. Clin Endocrinol (Oxf ) 1990, 33(1):119–131.
25. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA,
Guzick DS: Evidence for an association between metabolic cardiovascular
syndrome and coronary and aortic calcification among women with
polycystic ovary syndrome. J Clin Endocrinol Metab 2004, 89:5454–5461.
26. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, et al:
Postmenopausal women with a history of irregular menses and elevated
androgen measurements at high risk for worsening cardiovascular
event-free survival: results from the national institutes of health–national
heart, lung, and blood institute sponsored Women’s ischemia syndrome
evaluatio. J Clin Endocrinol Metab 2008, 93(4):1276–1284.
27. Talbott EO, Zborowski JV, Boudreaux MY, McHugh-Pemu KP, Sutton-Tyrrell K,
Guzick DS: The relationship between C-reactive protein and carotid
intima-media wall thickness in middle-aged women with polycystic ovary
syndrome. J Clin Endocrinol Metab 2004, 89(12):6061–6067.
28. Ketel IJ, Stehouwer CD, Henry RM, Serné EH, Hompes P, Homburg R, et al:
Greater arterial stiffness in polycystic ovary syndrome (PCOS) is an
obesity–but not a PCOS-associated phenomenon. J Clin Endocrinol Metab
2010, 95(10):4566–4575.
29. Cakal E, Ozkaya M, Engin-Ustun Y, Ustun Y: Serum lipocalin-2 as an insulin
resistance marker in patients with polycystic ovary syndrome.
J Endocrinol Invest 2011, 34(2):97–100.
30. Diamanti-Kandarakis E, Livadas S, Kandarakis SA, Margeli A, Papassotiriou I:
Serum concentrations of atherogenic proteins neutrophil gelatinase-
associated lipocalin and its complex with matrix metalloproteinase-9 are
significantly lower in women with polycystic ovary syndrome: hint of a
protective mechanism? Eur J Endocrinol 2008, 158(4):525–531.
31. Choi KM, Lee JS, Kim EJ, Baik SH, Seo HS, Choi DS, et al: Implication of
lipocalin-2 and visfatin levels in patients with coronary heart disease.
Eur J Endocrinol 2008, 158(2):203–207.
32. Zografos T, Haliassos A, Korovesis S, Giazitzoglou E, Voridis E, Katritsis D:
Association of neutrophil gelatinase-associated lipocalin with the severity
of coronary artery disease. Am J Cardiol 2009, 104(7):917–920.
33. Aydogdu A, Uckaya G, Tasci I, Baysan O, Tapan S, Bugan B, et al: The
relationship of epicardial adipose tissue thickness to clinical and
biochemical features in women with polycystic ovary syndrome. Endocr J
2012, 59(6):509–516.
34. Cakir E, Doğan M, Topaloglu O, Ozbek M, Cakal E, Vural MG, et al:
Subclinical atherosclerosis and hyperandrogenemia are independent risk
factors for increased epicardial fat thickness in patients with PCOS and
idiopathic hirsutism. Atherosclerosis 2013, 226(1):291–295.
doi:10.1186/1757-2215-7-24
Cite this article as: Sahin et al.: Epicardial adipose tissue thickness and
NGAL levels in women with polycystic ovary syndrome. Journal of
Ovarian Research 2014 7:24.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
